Journal
Tirzepatide Journal
The Tirzepatide Journal covers what changed and what it means: the end of routine compounding after the shortage resolution, what the approved product actually costs by route, what the head-to-head trial evidence establishes, how to appeal a coverage denial, and how to verify a pharmacy. Every piece carries its evidence status, sources, and verification dates.
Key takeaways
- 10 long-form pieces, each with data tables and charts.
- Coverage centres on the post-shortage landscape rather than a closed compounded market.
- Every claim carries an evidence status and a verification date.
- Clinical pieces are reviewed by a named, NPI-verified clinician.
- No provider pays for coverage, placement, or wording.
| Pieces published | 10 |
|---|---|
| Typical length | 1,200-1,800 words |
| Data modules | At least one table and one chart per piece |
| Review | Named clinical reviewers |
| Updated | 2026-07-22 |
What is worth reading first?
If you were using a compounded programme, start with the piece on what replaced it. If you are deciding whether to start, the cost analysis and the head-to-head evidence are the two that change decisions most. If you have commercial insurance, the appeals piece is probably worth more to you than everything else combined.
Compounded Tirzepatide Is Over. Here Is What Replaced It.
Routine compounding of tirzepatide ended in early 2025. The FDA declared the shortage resolved on 2 October 2024, reaffirmed it by declaratory order o…
CostWhat Tirzepatide Actually Costs in 2026
Tirzepatide now costs between a modest insurance copay and roughly $1,086 a month, and the difference is determined almost entirely by insurance statu…
EvidenceTirzepatide Beat Semaglutide Head to Head. What That Does and Does Not Settle.
SURMOUNT-5 randomised 751 adults with obesity to tirzepatide or semaglutide for 72 weeks at maximum tolerated doses. Tirzepatide produced greater weig…
EvidenceWhat Actually Happens When You Stop Tirzepatide
SURMOUNT-4 answered this directly. After a 36-week open-label lead-in in which everyone lost weight on tirzepatide, 670 adults were randomised to cont…
AccessHow to Appeal an Insurance Denial for Weight-Management Coverage
For anyone with commercial insurance, a coverage appeal is usually worth more than any price comparison. Denials commonly rest on a plan exclusion for…
CostWhy Advertised GLP-1 Prices Almost Always Understate What You Pay
Advertised telehealth prices for GLP-1 programmes routinely understate the real monthly cost, and the mechanisms are consistent enough to be predictab…
BrandsZepbound and Mounjaro Are the Same Molecule. Why the Rules Differ.
Zepbound and Mounjaro both contain tirzepatide, made by the same manufacturer. They differ in approved indication — Zepbound for chronic weight manage…
ProvidersTen Questions Worth Asking a GLP-1 Telehealth Provider in 2026
The questions that mattered during the compounding era were mostly about price. After the shortage resolution closed that market, the questions that m…
SafetyTirzepatide Side Effects: What the Trials Actually Recorded
Gastrointestinal effects dominate the adverse-event tables in every SURMOUNT trial: nausea, diarrhoea, vomiting and constipation, predominantly mild t…
PharmacyHow to Verify a Pharmacy Now That the Shortage Rules Have Changed
Pharmacy verification mattered during the compounding era because no premarket FDA review stood behind the product. It matters more now, because any s…
What are the limits of what this page can tell you?
Every page on this site rests on a specific published evidence, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for a qualified professional.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
The following would trigger a revision to this page, recorded in its change history:
- New primary evidence bearing directly on tirzepatide journal.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 5 technical terms this page uses, including GLP-1, NPI, compounded, maximum tolerated dose — in the specific sense used above.
| GLP-1 | Glucagon-like peptide-1. An incretin hormone that slows gastric emptying, signals satiety to the brain, stimulates glucose-dependent insulin release, and suppresses inappropriate glucagon secretion. |
|---|---|
| NPI | National Provider Identifier. A number issued to clinicians in the United States and searchable in the public CMS NPPES registry, which is how a named reviewer's identity can be checked. |
| compounded | Prepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial. |
| maximum tolerated dose | The highest dose an individual can take without unacceptable adverse effects. Trials frequently escalate to this point rather than to a fixed dose, which means participants in one arm may be taking different amounts. |
| open-label | A trial in which participants and investigators know which treatment is being given. SURMOUNT-5 was open-label, a genuine limitation, though weight is an objective measurement less vulnerable to expectation than a self-reported outcome. |
Frequently asked questions
How often is the journal updated?
Pieces are revised when the underlying evidence changes, and each carries its own change history.
Are these sponsored?
No. No provider or manufacturer pays for coverage, placement, or wording.
Who reviews the clinical content?
Named reviewers with NPI records verified against the CMS NPPES registry — see the reviewer directory.
Can I reuse the charts?
The underlying data is published on the data page.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.